Verona Pharma logo

VRNA - Verona Pharma Share Price

$9.13 -0.2  -1.8%

Last Trade - 26/02/21

Small Cap
Market Cap £343.7m
Enterprise Value £143.2m
Revenue £n/a
Position in Universe th / 6718
Unlock VRNA Revenue
Relative Strength (%)
1m +13.6%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -40.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, VeronaPharma Plc revenues was not reported. Net loss increased34% to £41.4M. Higher net loss reflects General andadministrative costs increase from £7.5M to £18.1M(expense), Effective G/L on Derivatives - Hedging decreasefrom £2.7M (income) to £0K, Other Non Operating I/Eincrease from £112K to £1.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


VRNA Revenue Unlock VRNA Revenue

Net Income

VRNA Net Income Unlock VRNA Revenue

Normalised EPS

VRNA Normalised EPS Unlock VRNA Revenue

PE Ratio Range

VRNA PE Ratio Range Unlock VRNA Revenue

Dividend Yield Range

VRNA Dividend Yield Range Unlock VRNA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VRNA EPS Forecasts Unlock VRNA Revenue
Profile Summary

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. The Company is developing ensifentrine, the treatment for respiratory disease. Ensifentrine is an inhaled therapy that acts as both a bronchodilator and an anti-inflammatory agent in one compound. In addition to nebulized ensifentrine, the Company has developed dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) formulations of ensifentrine for less severe patients. The Company’s subsidiaries include Verona Pharma Inc. and Rhinopharma Limited.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated February 24, 2005
Public Since March 30, 2005
No. of Shareholders: n/a
No. of Employees: 22
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 51,784,787
Free Float (0.0%)
Eligible for
VRNA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for VRNA
Upcoming Events for VRNA
Frequently Asked Questions for Verona Pharma
What is the Verona Pharma share price?

As of 26/02/21, shares in Verona Pharma are trading at $9.13, giving the company a market capitalisation of £343.7m. This share price information is delayed by 15 minutes.

How has the Verona Pharma share price performed this year?

Shares in Verona Pharma are currently trading at $9.13 and the price has moved by 37.98% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Verona Pharma price has moved by 4.71% over the past year.

What are the analyst and broker recommendations for Verona Pharma?

There are no analysts currently covering Verona Pharma.

When will Verona Pharma next release its financial results?

Verona Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Verona Pharma dividend yield?

Verona Pharma does not currently pay a dividend.

Does Verona Pharma pay a dividend?

Verona Pharma does not currently pay a dividend.

When does Verona Pharma next pay dividends?

Verona Pharma does not currently pay a dividend.

How do I buy Verona Pharma shares?

To buy shares in Verona Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Verona Pharma?

Shares in Verona Pharma are currently trading at $9.13, giving the company a market capitalisation of £343.7m.

Where are Verona Pharma shares listed? Where are Verona Pharma shares listed?

Here are the trading details for Verona Pharma:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: VRNA
What kind of share is Verona Pharma?

We were not able to load our ranking data for Verona Pharma

Is there a Verona Pharma share price forecast 2021?

Shares in Verona Pharma are currently priced at $9.13. At that level they are trading at 1.52% discount to the analyst consensus target price of 0.00.

Analysts covering Verona Pharma currently have a consensus Earnings Per Share (EPS) forecast of -1.5250124884 for the next financial year.

How can I tell whether the Verona Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verona Pharma. Over the past six months, the relative strength of its shares against the market has been 15.5%. At the current price of $9.13, shares in Verona Pharma are trading at 38.5% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Verona Pharma PE Ratio?

We were not able to find PE ratio data for Verona Pharma.

Who are the key directors of Verona Pharma?

We were unable to find the directors for Verona Pharma.

Who are the major shareholders of Verona Pharma?

Here are the top five shareholders of Verona Pharma based on the size of their shareholding:

OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 10.99% (5.69m shares)
New Enterprise Associates (NEA) Venture Capital
Percentage owned: 9.86% (5.11m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 9.84% (5.10m shares)
Vivo Capital, LLC Venture Capital
Percentage owned: 5.88% (3.05m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 5.58% (2.89m shares)
Similar to VRNA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.